Do you want to provide some evidence for this outlandish claim that 89% of drugs in phase 2 trials that progress to phase 3 get FDA approval? Are you really suggesting that only 11% of drugs that enter phase 3 trials fail?
Not talking about the science of a biotech company when discussing its commercial prospects is like ignoring geology when discussing a mining exploration company. The science is the base to the value of a biotech company.
What’s new this time?, page-22
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
